Pathogenesis and Treatment of Polycystic Ovary Syndrome

New England Journal of Medicine

Volumn 318, Issue 9, 1988, Pages 558-562

  Mckenna, T Joseph ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CYPROTERONE; DEXAMETHASONE; SPIRONOLACTONE;

ADULT; FEMALE; HUMAN; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0023864662     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198803033180906     Document Type: Review

References (54)

1. Kirschner MA, Zucker IR, Jespersen D. Idiopathic hirsutism — an ovarian abnormality. N Engl J Med 1976; 294: 637–40.
2. Yen SSC, Vela P, Rankin J. Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab 1970; 30: 435–42.
3. Oake RJ. Davies SJ, McLachlan MSF, Thomas JP. Plasma testosterone in adrenal and ovarian vein blood of hirsute women. Q J Med 1974; 43: 603–13.
4. Rosenfield R. Congenital adrenal hyperplasia and reproductive function in females. In: Flamigni C, Venturoli S, Givens JR, eds. Adolescence in females. Chicago: Year Book, 1985:373–87.
5. Yen SSC. The polycystic ovary syndrome. Clin Endocrinol (Oxf) 1980; 12: 177–207.
6. Corenblum B. Hyperprolactinemic polycystic ovary syndrome. In: Mahesh VB, Greenblatt RB, eds. Hirsutism and virilism: pathogenesis, diagnosis and management. Boston: John Wright/PSG, 1983:239–46.
7. Poretsky L, Kalin MF. The gonadotropic function of insulin. Endocr Rev 1987; 8: 132–41.
8. Rebar R, Judd HL, Yen SSC, Rakoff J, Vandenberg G, Naftolin F. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 1976; 57: 1320–9.
9. Ross GT. Correlates of gonadotropins with ovarian morphology and function throughout life. In: Vaitukaitis JL, ed. Clinical reproductive neuroendocrinology. New York: Elsevier Press, 1982:1–17.
10. Goldzieher JW, Green JA. The polycystic ovary. 1. Clinical and histologic features. J Clin Endocrinol Metab 1962; 22: 325–38.
11. Nisker JH, Hammond GL, Davidson J, et al. Serum sex hormone–binding globulin capacity and the percentage of free estradiol in postmenopausal women with and without endometrial carcinoma: a new biological basis for the association between obesity and endometrial carcinoma, Am J Obstet Gynecol 1980; 138: 637–42.
12. Yen SSC, Vela P, Ryan KJ. Effect of clomiphene citrate in polycystic ovary syndrome: relationship between serum gonadotropin and corpus luteum function. J Clin Endocrinol Metab 1970; 31: 7–13.
13. McKenna TJ, Cunningham SK, Loughlin T. Ovarian estradiol secretion is suppressed and the LH/FSH ratio is elevated in the common forms of amenorrhoea. In: Genazzani AR, Volpe A, Facchinetti F, eds. Research on gynaecological endocrinology. Carnforth, England: Parthenon, 1986:157–68.
14. Siiteri PK, McDonald PC. Role of extraglandular estrogen in human endocrinology. In: Greep RO, Astwood EB, eds. Handbook of physiology. Vol. 2. Endocrinology. Washington, D.C.: American Physiology Society, 1973:615–29.
15. Kase N, Kowal J, Perloff W, Soffer LJ. In vitro production of androgens by virilizing adrenal adenoma and associated polycystic ovaries. Acta Endocrinol (Copenh) 1963; 44: 15–9.
16. Moore A, Magee F, Cunningham SK, Culliton M, McKenna TJ. Adrenal abnormalities in idiopathic hirsutism. Clin Endocrinol (Oxf) 1983; 18: 391–9.
17. Loughlin T, Cunningham S, Moore A, Culliton M, Smyth PPA, McKenna TJ. Adrenal abnormalities in polycystic ovary syndrome. J Clin Endocrinol Metab 1986; 62: 142–7.
18. Dewis P, Newman M, Ratcliffe WA, Anderson DC. Does testosterone affect the normal menstrual cycle? Clin Endocrinol (Oxf) 1986; 24: 515–21.
19. McKenna TJ, Cunningham SK, Loughlin T. The adrenal cortex and virilization. Clin Endocrinol Metab 1985; 14: 997–1020.
20. Loughlin T, Cunningham SK, Culliton M, Smyth PPA, Meagher DJ, McKenna TJ. Altered androstenedione and estrone dynamics associated with abnormal hormonal profiles in amenoirheic subjects with weight loss or obesity. Fertil Steril 1985; 43: 720–5.
21. Adams J, Poison DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J 1986; 293: 355–9.
22. Abraham GE, Chakmakjian ZH, Buster JE, Marshall JR. Ovarian and adrenal contributions to peripheral androgens in hirsute women. Obstet Gynecol 1975; 46: 169–73.
23. Lachelin GCL, Barnett M, Hopper BR, Brink G, Yen SSC. Adrenal function in normal women and women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1979; 49: 892–8.
24. Givens JR, Andersen RN, Ragland JB, Wiser WL, Umstot ES. Adrenal function in hirsutism. 1. Diurnal change and response of plasma androstenedione, testosterone, 17-hydroxyprogesterone, cortisol, LH and FSH to dexamethasone and 1/2 unit of ACTH. J Clin Endocrinol Metab 1975; 40: 988–1000.
25. Kandeel FR, London DR. Butt WR, et al. Adrenal function in subgroups of the PCO syndrome assessed by a long ACTH test. Clin Endocrinol (Oxf) 1980; 13: 601–12.
26. Levine LS, Korth-Schutz S, Saenger P, Sweeney WJ III, Belling CG, New MI. Disordered puberty in treated congenital adrenal hyperplasia. In: Lee PA, Plotnick LP, Kowarski AA, Migeon CJ, eds. Congenital adrenal hyperplasia. Baltimore: University Park Press, 1977:361–78.
27. Stein IF. Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29: 181–91.
28. Harlass FE, Plymate SR, Fariss BL, Belts RP. Weight loss is associated with correction of gonadotropin and sex steroid abnormalities in the obese anovulatory female. Fertil Steril 1984; 42: 649–52.
29. Corenblum B, Taylor PJ. The hyperprolactinemic polycystic ovary syndrome may not be a distinct entity. Fertil Steril 1982; 38: 549–52.
30. Pehrson JJ, Vaitukaitis J, Longcope C. Bromocriptine, sex steroid metabolism, and menstrual patterns in the polycystic ovary syndrome. Ann Intern Med 1986; 105: 129–30.
31. Seppälä M, Hirvonen E. Raised serum prolactin levels associated with hirsutism and amenorrhoea. Br Med J 1975; 4: 144–5.
32. Wortsman J, Hirschowitz JS. Galactorrhea and hyperprolactinemia during treatment of polycystic ovary syndrome. Obstet Gynecol 1980; 55: 460–3.
33. del Pozo ES, Falaschi P. Prolactin and cyclicity in polycystic ovary syndrome: role of estrogens and the dopaminergic system. Prog Reprod Biol 1980; 6: 252–9.
34. Yen SSC, Ehara Y, Siler TM. Augmentation of prolactin secretion by estrogen in hypogonadal women. J Clin Invest 1974; 53: 652–5.
35. Parker LN, Odell DD. Control of adrenal androgen secretion. Endocr Rev 1980; 1: 392–410.
36. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980; 50: 113–6.
37. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983; 57: 356–9.
38. Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 1986; 62: 904–10.
39. Roth J, Grunfeld C. Mechanism of action of peptide hormones and catecholamines. In: Wilson JD, Foster DW, eds. Textbook of endocrinology. 7th ed. Philadelphia: W.B. Saunders, 1985:76–122.
40. Adashi EY, Resnick CE, D'Ercole AJ, Svoboda ME, Van Wyk JJ. Insulinlike growth factors as intraovarian regulators of granulosa cell growth and function. Endocr Rev 1985; 6: 400–20.
41. Glass AR, Burman KD, Dahms WT, Boehm TM. Endocrine function in human obesity. Metabolism 1981; 30: 89–104.
42. Stahl NL, Teeslink CR, Beauchamps G, Greenblatt RB. Serum testosterone levels in hirsute women: comparison of adrenal, ovarian and peripheral vein values. Obstet Gynecol 1973; 41: 650–4.
43. Northrop G, Archie JT, Patel SK, Wilbanks GD. Adrenal and ovarian vein androgen levels and laparoscopic findings in hirsute women. Am J Obstet Gynecol 1975; 122: 192–8.
44. Givens JR. Role of oral contraceptives in the treatment of hyperandrogenism of hirsute women. In: Mahesh VB. Greenblatt RB, eds. Hirsutism and virilism: pathogenesis, diagnosis and management. Boston: John Wright/PSG, 1983:351–67.
45. Steinberger E, Smith KD, Rodriquez-Rigau LJ. Hyperandrogenism and female infertility. In: Crosignani PG, Rubin BL, eds. Endocrinology of human infertility: new aspects. Proceedings of the Serono Clinical Colloquia on Reproduction. No. 2. London: Academic Press, 1981:327–42.
46. Biffignandi P, Massuchetti C, Molianatti GM. Female hirsutism: pathophysiological considerations and therapeutic implications. Endocr Rev 1984; 5: 489–513.
47. McKenna TJ, Cunningham S. Adrenal secretion and ovarian dysfunction. In: D'Agata R, Chrousos GP, eds. Recent advances in adrenal function and regulation. New York: Raven Press, 1987:151–63.
48. McKenna TJ, Cunningham SK. A role for Diane in the management of hirsutism. Acta Derm Venereol (Stockh) (in press).
49. Lobo RA, Shoupe D, Serafini P. Brinton D, Horton R. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil Steril 1985; 43: 200–5.
50. Kistner RW. The use of clomiphene citrate in the treatment of anovulation. Semin Drug Treat 1973; 3: 159–75.
51. McKenna TJ, Loughlin T, Smyth PPA, Cunningham S. The pathogenesis and treatment of the polycystic ovary syndrome. In: Flamigni C, Venturoli S, Givens JR, eds. Adolescence in females. Chicago: Year Book, 1985:405–19.
52. Couzinet B, Le Strat N, Brailly S, Schaison G. Comparative effect of cyproterone acetate and a long-acting gonadotropin-releasing hormone agonist in polycystic ovarian disease. J Clin Endocrinol Metab 1986; 63: 1031–5.
53. Nappi C. Urinary follicle-stimulating hormone treatment in clomipheneresistant anovulatory women with polycystic ovarian disease. In: Genazzani AR, Volpe A, Facchinetti F, eds. Gynaecological endocrinology: the proceedings of the First International Congress in Gynaecological Endocrinology. Carnforth, England: Parthenon, 1987:335–45.
54. Armitage M, Wilkin T, Dewbury K. Successful treatment of infertility due to polycystic ovary disease using a combination of luteinising hormone-releasing hormone agonist and low dosage menotrophin. Br Med J 1987; 295: 96.